T
Teodora Staeva
Researcher at JDRF
Publications - 11
Citations - 665
Teodora Staeva is an academic researcher from JDRF. The author has contributed to research in topics: NOD mice & Clinical trial. The author has an hindex of 8, co-authored 11 publications receiving 625 citations. Previous affiliations of Teodora Staeva include Memorial Sloan Kettering Cancer Center & University of Wisconsin-Madison.
Papers
More filters
Journal ArticleDOI
Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes.
Martha Campbell-Thompson,Clive Wasserfall,John S. Kaddis,Anastasia Albanese-O'Neill,Teodora Staeva,Concepcion Nierras,Jayne M Moraski,Patrick Rowe,Roberto Gianani,George S. Eisenbarth,James M. Crawford,Desmond A. Schatz,Alberto Pugliese,Mark A. Atkinson +13 more
TL;DR: The Network for Pancreatic Organ Donors with Diabetes was established to recover and characterize pancreata and related organs from cadaveric organ donors with various risk levels for type 1 diabetes.
Journal ArticleDOI
Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN–JDRF Type 1 Diabetes Combination Therapy Assessment Group
TL;DR: A Type 1 Diabetes Combination Therapy Assessment Group was convened and the recommendations, the recommendations of which are discussed in this Perspective paper, are discussed.
Journal Article
Multiple Subtypes of Serotonin Receptors Are Expressed in Rat Sensory Neurons in Culture
Joanne J. Chen,Michael R. Vasko,Xiaoping Wu,Teodora Staeva,Melvyn Baez,John M. Zgombick,David Lee Nelson +6 more
TL;DR: The identification of multiple subtypes of serotonin receptors expressed in cultured embryonic sensory neurons suggests that DRG neuronal cultures may be an excellent model to examine the direct effects of serotonin on the activity of these sensory neurons.
Journal ArticleDOI
Recent Lessons Learned From Prevention and Recent-Onset Type 1 Diabetes Immunotherapy Trials
TL;DR: In this paper, the authors present and elaborates on key emerging questions and recommendations for future immunotherapy trials in Type 1 diabetes (T1D) and suggest that such strategies could accelerate the development of therapies with tangible clinical benefit.
Journal ArticleDOI
A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAT1 and stabilizes c-Jun.
TL;DR: The mechanism by which VDR elicits its transcriptional inhibitory effect is described, which effectively block the NFAT1–AP-1 activation complex, resulting in an attenuation of activated GM-CSF transcription.